MedTrace Logo

Computer-assisted Cognitive Rehabilitation (CACR), Placebo CACR and Psycho-stimulants in the Treatment of ADHD

NCT01675804 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2015-04-06

No results posted yet for this study

Summary

Current research aimed to compare the efficacy of computer-assisted cognitive rehabilitation (CACR), stimulant drugs and Placebo CACR on executive functions and clinical symptoms of children with attention deficit/hyperactivity disorder (ADHD).

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

OTHER

Computerized cognitive rehabilitation

\- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.

DRUG

Ritalin

-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.

OTHER

Placebo CACR [PCACR]

PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.

Sponsors & Collaborators

  • Allameh Tabatabai University

    lead OTHER

Principal Investigators

  • Saeed Azami, MSc · Candidate for PhD in Psychology, Department of Psychology, Semnan University, Semnan, Iran

  • Alireza Moghadas, PhD · Department of Clinical Psychology, Allameh Tabatabaei University, Tehran, Iran.

  • Faramarz Sohrabi, PhD · Department of Clinical Psychology, Allameh Tabatabaei University, Tehran, Iran.

  • Morteza Nazifi, PhD · Department of psychology, University of Bojnord, Bojnord, Iran.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
7 Years
Max Age
12 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-04-30
Completion
2012-05-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01675804 on ClinicalTrials.gov